Nanophoria S.r.l.

a. NanoPhoria is a pre-clinical stage biotech company that is developing non-viral drug delivery platform based on inorganic nanoparticles.l. NanoPhoria’s core technology is a non-viral, nano-in-micro delivery platform designed for inhalable administration of biologics. The company’s lead product candidate, NP-MP1, is being developed for the treatment of heart failure with reduced ejection fraction (HFrEF), a serious and debilitating condition affecting millions of patients worldwide. At the molecular level, HFrEF is associated with dysregulation of L-type calcium channels in cardiomyocytes, which play a central role in cardiac contractility. The active principle of NP-MP1 is a proprietary mimetic peptide designed to modulate intracellular mechanisms involved in calcium channel trafficking. Preclinical studies in small and large animal models have demonstrated the peptide’s ability to regulate L-type calcium channel localization and function within cardiomyocytes, supporting its potential classification as a disease-modifying therapy. NP-MP1 is formulated as a three-level inhalable dry powder. The mimetic peptides are first encapsulated in calcium-phosphate nanoparticles, which are then embedded within lung-compatible, mannitol-based microparticles. Upon inhalation, the microparticles reach the deep lung, dissolve in the alveolar space, and release peptide-loaded nanoparticles into the bloodstream. These nanoparticles subsequently reach the heart, where they are taken up by cardiomyocytes, enabling intracellular release of the peptide and restoration of physiological calcium channel function.

1. Series A

   Jan 20, 2026

   Amount

   $17M

   Investors

   Locked

2. Series A

   Oct 6, 2025

   Amount

   $80M

   Investors

   Locked

3. Seed

   May 12, 2022

   Amount

   $3.6M

   Investors

   Locked